Clearmind Medicine Inc. (NASDAQ:CMND) Stock Short Interest Report for September

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 14,819 shares, a drop of 58.5% from the September 15th total of 35,733 shares. Based on an average trading volume of 259,644 shares, the short-interest ratio is presently 0.1 days. Currently, 11.4% of the company’s shares are short sold.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Clearmind Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 20th.

Clearmind Medicine Stock Up 1.8%

Shares of NASDAQ:CMND traded up $0.12 during trading on Thursday, reaching $6.41. The stock had a trading volume of 5,047 shares, compared to its average volume of 116,473. The company has a market capitalization of $3.27 million, a P/E ratio of -0.16 and a beta of 0.93. Clearmind Medicine has a one year low of $5.25 and a one year high of $3,840.00. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 0.01. The firm’s 50-day simple moving average is $9.92 and its 200 day simple moving average is $27.89.

Clearmind Medicine (NASDAQ:CMND) last posted its quarterly earnings data on Thursday, September 10th. The company reported ($4.56) earnings per share for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors.

Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns.

Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly.